

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT
MCV4 OBTAINS CLINICAL TRIAL APPROVAL

This announcement is made by CanSino Biologics Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Company is pleased to announce that, the Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (the “**MCV4**”) developed by the Group has obtained clinical trial approval granted by the National Medical Products Administration of the People's Republic of China to initiate relevant clinical trials in people aged 7-59 years old.

According to publicly available data, the global market share in terms of adult vaccines has rapidly increased from 35.58% in 2017 to 50.38% in 2021, overtaking the pediatric vaccine market to become the mainstay of the vaccine consumption structure. The domestic market size in terms of adult vaccines (excluding the COVID-19 vaccine) reached RMB42.74 billion in 2021, with the market share rising rapidly from 32% in 2018 to 56% in 2021. With the rising awareness of health precautions and vaccination among the public, the adult vaccine market is expected to further expand.

Due to the implementation of the immunization plan, children have been vaccinated against meningitis and have developed an effective level of immunity. However, due to the decreasing level of antibodies in adolescents and adults, some of them have lost their immune resistance to the meningitis bacterium and become susceptible to the disease. Pandemic outbreaks may occur in occasions such as schools and dormitories. As the Company's MCV4 has obtained clinical trial approval to initiate relevant clinical trials in people aged 7-59 years old, we intend to expand the applicable group of MCV4 to adolescents and adults to provide better protection and meet the demand for adolescent and adult meningitis vaccines.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, June 27, 2023

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.